Decades ago, science fiction authors imagined a future where one device could analyze and diagnose any condition. . That device is rapidly becoming a reality – in the form of Software as a Medical Device (SaMD) apps running on iOS and Android devices. Our personal smartphones, tablets, smartwatches and earbuds will soon be able to collect a wide variety of clinical-grade diagnostic data using the consumer-grade sensors embedded in their personal electronics.
Despite the dozens (if not hundreds) of firms working in this space, and a phenomenal/first major exit (Pfizer buying ResApp for $116M USD!), this category of diagnostic device has heretofore gone unnamed. We’re dubbing it:
Clinical Diagnostics on Consumer Electronics (CD-CE)
By moving diagnosis from the Point of Care and to our Points of Living, CD-CE could dramatically improve healthcare outcomes through earlier diagnosis, help close gaps in healthcare access and equity and help us to collectively bend the healthcare cost curve.
But like any other promising innovation in healthcare, smashing success for CD-CE is far from guaranteed. Along the way, these groundbreaking products will need to demonstrate clinical and economic value. They will also need to overcome the concerns of a diverse range of providers, patients, medical device and pharma manufacturers, regulators, payers and consumer technology companies.
Join us as we dive into these fascinating and important issues.
